Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases

Date

21 Oct 2023

Session

Poster session 20

Topics

Clinical Research;  Cancer Biology;  Translational Research;  Molecular Oncology;  Therapy

Tumour Site

Non-Small Cell Lung Cancer;  Central Nervous System Malignancies

Presenters

Sara Hijazo-Pechero

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

S. Hijazo-Pechero1, A. Alay Badosa2, N. Vilariño3, J. Brenes Castro3, L. Moliner4, M. Mosteiro3, N. Vidal5, C. Muñoz-Pinedo1, J. Bruna6, E. Nadal3

Author affiliations

  • 1 Preclinical And Experimental Research In Thoracic Tumors, IDIBELL - Bellvitge Biomedical Research Institute, 08908 - Hospitalet de Llobregat/ES
  • 2 Bioinformatics For Precision Oncology, ICO-Catalan Institute of Oncology, 08908 - Hospitalet de Llobregat/ES
  • 3 Medical Oncology, ICO-Catalan Institute of Oncology, 08908 - L'Hospitalet de Llobregat/ES
  • 4 Medical Oncology, ICO-Catalan Institute of Oncology, 08908 - Hospitalet de Llobregat/ES
  • 5 Pathology, HUB-Bellvitge University Hospital, 08907 - Hospitalet de Llobregat/ES
  • 6 Neuro-oncology, ICO-Catalan Institute of Oncology, 08908 - Barcelona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1419P

Background

Brain metastases (BM) are a frequent complication in patients with non-small lung cancer (NSCLC). Treating BM is challenging as the blood-brain barrier can limit intracranial drug delivery. Data from different trials suggest that antibody-drug conjugates (ADC) can have clinically relevant intracranial activity. This study aims to characterize the gene expression of ADC targets in NSCLC-BM to guide treatment decisions.

Methods

Gene expression data from 125 BM resected from patients with NSCLC were obtained from 3 public datasets. Gene expression of 14 ADC targets (ERBB2, ERBB3, TACSTD2, MET, GPNMB, PTK7, MSLN, CD276, TF, AXL, EGFR, SLC34A2, CEACAM5 and ROR2) was evaluated to identify those consistently expressed across the cohorts. Additionally, hierarchical clustering was used to stratify NSCLC-BM, in each dataset separately, based on the combined relative gene expression of the common 25% most variable genes: MSLN, CEACAM5 and SLC34A2. Furthermore, association between clusters and clinical covariates was assessed for one of the datasets with available data (N=63).

Results

Gene expression evaluation showed that TACSTD2 (Trop-2) was ubiquitously highly expressed across datasets, suggesting that TACSTD2 could be a promising ADC target for NSCLC-BM. Contrarily, ROR2 showed consistently lower expression and would probably not be a good candidate in NSCLC-BM. Transcriptional patterns from the 3 most variable ADC targets (MSLN, CEACAM5, and SLC34A2) yielded common subgroups in all datasets defined by the following expression levels (respectively): High/High/High, Low/High/High, High/Low/Low. These groups did not correlate with clinical covariates.

Conclusions

Gene expression evaluation of ADC targets in NSCLC-BM resulted in the identification of TACSTD2 expression across all datasets. TACSTD2 might be a promising ADC target for patients with NSCLC with BM. Further validation is warranted in terms of protein expression. Our results underscore the potential value of gene expression profiling to identify new targets and improve patient selection in the context of NSCLC-BM ADC therapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Instituto de Salud Carlos III (CM22/00035).

Disclosure

E. Nadal: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Boehringer Ingelheim, Lilly, Janssen, Pfizer, Merck Serono, Daiichi Sankyo, AstraZeneca, Takeda, Amgen, Sanofi, Qiagen, Janssen; Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Boehringer Ingelheim, Lilly, Pfizer, Sanofi, AstraZeneca, Takeda, Amgen, Qiagen, Janssen; Financial Interests, Personal and Institutional, Funding, Clinical trial funded by Roche: Roche; Financial Interests, Personal and Institutional, Funding, BMS funded a clinical trial: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding, Merck Serono funded a clinical trial: Merck Serono; Non-Financial Interests, Advisory Role: Pfizer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.